secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sunshine Biopharma Inc. (SBFM)
CIK:        0001402328
Form:       8-K
Filed at:   2024-03-06T23:59:59+00:00
Accession:  0001683168-24-001357
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 1.01, 3.02, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Sunshine Biopharma CEO buys voting-preferred shares for $10K; 1-for-200 reverse split approved
--------------------------------------------------------------------------------

- CEO Steve Slilaty purchased 100,000 Series B Preferred shares for $10,000, each with 1,000 votes.
- Preferred stock is non-convertible, non-redeemable, with $0.10 liquidation preference superior to common.
- Slilaty, holder of ~57.4% voting power, approved by written consent a reverse stock split up to 1-for-200.
- Reverse split up to 1-for-200 aims to regain Nasdaq $1.00 minimum bid; effective 20 days after mailing info statement filed March 5.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1402328/000168316824001357/0001683168-24-001357-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1402328/000168316824001357/sunshine_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-001357

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer